Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies

Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies

Abstract Background The World Health Organization (WHO) declared the end of the COVID-19 (SARS-CoV-2) global public health emergency on May 5, 2023, but its long-term consequences have still been haunting the global population. Post-acute sequelae of COVID-19 (PASC) and long-term COVID-19 are seriou...

Full description

Saved in:
Bibliographic Details
Main Authors: Fernando Valerio-Pascua, Fernando Baires, Anupamjeet Kaur Sekhon, Mari L. Tesch, Estela Jackeline Pineda, Syed A. A. Rizvi, Jarmanjeet Singh, David Abraham Cortes-Bandy, Amy C. Madril, Jana Radwanski, Anita S. Lewis, Miguel Sierra-Hoffman, Mark L. Stevens, Franck F. Rahaghi
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Infectious Diseases
Subjects:
COVID-19
SARS-CoV-2
Intranasal chlorpheniramine
Efficacy
Randomized clinical trial
Double-blind
Online Access:https://doi.org/10.1186/s12879-024-10211-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12879-024-10211-8

Similar Items